Eplerenone for the Treatment of Central Serous Chorioretinopathy

Key facts

Sponsor

Wills Eye

Principal Investigator

Mitchell Fineman, MD

Mid Atlantic Retina

Intervention

25mg Eplerenone(drug)

Enrollment

108 enrolled

Eligibility

18 years · All sexes

Timeline

2013 – 2015

Study locations (10)

• Mid Atlantic Retina, Cherry Hill, New Jersey, United States
• Mid Atlantic Retina, Marlton, New Jersey, United States
• Mid Atlantic Retina, Mays Landing, New Jersey, United States
• Mid Atlantic Retina, Bala-Cynwyd, Pennsylvania, United States
• Mid Atlantic Retina, Bethlehem, Pennsylvania, United States
• Mid Atlantic Retina, Huntingdon Valley, Pennsylvania, United States
• Mid Atlantic Retina, Lansdale, Pennsylvania, United States
• Mid Atlantic Retina, New Wilmington, Pennsylvania, United States
• Mid Atlantic Retina, Newtown Square, Pennsylvania, United States
• Mid Atlantic Retina, Plymouth Meeting, Pennsylvania, United States

Collaborators

Mid Atlantic Retina

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Central serous chorioretinopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06527326
  the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
  Second Affiliated Hospital, School of Medicine, Zhejiang University
• RECRUITINGNCT06346405
  Central Serous Chorioretinopathy and Micropulse Laser Treatment
  Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• RECRUITINGNANCT05570591
  Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
  Nova Eye Medical Pty Ltd.
• RECRUITINGNCT05589974
  Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
  Helse Stavanger HF

See all trials for Central serous chorioretinopathy →